Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Argus Health
Cipla
Deloitte
Boehringer Ingelheim
Accenture

Generated: April 24, 2019

37 Drugs Facing NCE-1 / Abbreviated New Drug Application acceptance dates in 2019 - 2020

Loss of Exclusivity / End of Market Exclusivity Period dates

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "37 Drugs Facing NCE-1 / Abbreviated New Drug Application acceptance dates in 2019 - 2020" DrugPatentWatch.com thinkBiotech, 2019 www.drugpatentwatch.com/p/nce-1/.
Media collateral
These NCE-1 dates indicate the first opportunity for generic drug companies to file Abbreviated New Drug Applications (ANDAs) for generic entry into branded drug markets. Generic launch is dependent on many factors, including FDA approval and patents. This information is provided as a rough estimate of generic application, and does not indicate when generics will launch. For more information see the complete DrugPatentWatch database.
VIBERZI

Generic name: eluxadoline
NCE-1 Date: May 2019

Drug Price Trends for VIBERZI
VIBERZI is a drug marketed by Allergan Holdings. There are thirteen patents protecting this drug.

This drug has one hundred and thirty-two patent family members in thirty-seven countries. There has been litigation on patents covering VIBERZI

See drug price trends for VIBERZI.

The generic ingredient in VIBERZI is eluxadoline. There are two drug master file entries for this API. Additional details are available on the eluxadoline profile page.

LONSURF

Generic name: tipiracil hydrochloride; trifluridine
NCE-1 Date: September 2019

LONSURF is a drug marketed by Taiho Oncology. There are three patents protecting this drug.

This drug has fifty-five patent family members in twenty-six countries.

See drug price trends for LONSURF.

The generic ingredient in LONSURF is tipiracil hydrochloride; trifluridine. There are two drug master file entries for this API. Additional details are available on the tipiracil hydrochloride; trifluridine profile page.

RYZODEG 70/30

Generic name: insulin aspart; insulin degludec
NCE-1 Date: September 2019

RYZODEG 70/30 is a drug marketed by Novo. There are seventeen patents protecting this drug.

This drug has one hundred and sixty-nine patent family members in twenty-three countries. There has been litigation on patents covering RYZODEG 70/30

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Additional details are available on the insulin aspart; insulin degludec profile page.

TRESIBA

Generic name: insulin degludec
NCE-1 Date: September 2019

TRESIBA is a drug marketed by Novo. There are sixteen patents protecting this drug.

This drug has one hundred and sixty-one patent family members in twenty-three countries. There has been litigation on patents covering TRESIBA

See drug price trends for TRESIBA.

The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Additional details are available on the insulin degludec profile page.

XULTOPHY 100/3.6

Generic name: insulin degludec; liraglutide
NCE-1 Date: September 2019

XULTOPHY 100/3.6 is a drug marketed by Novo. There are eighteen patents protecting this drug.

This drug has two hundred and eighty-three patent family members in twenty-seven countries. There has been litigation on patents covering XULTOPHY 100/3.6

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Additional details are available on the insulin degludec; liraglutide profile page.

DESCOVY

Generic name: emtricitabine; tenofovir alafenamide fumarate
NCE-1 Date: November 2019

Drug Price Trends for DESCOVY
DESCOVY is a drug marketed by Gilead Sciences Inc. There are six patents protecting this drug.

This drug has three hundred and four patent family members in fifty-nine countries. There has been litigation on patents covering DESCOVY

See drug price trends for DESCOVY.

The generic ingredient in DESCOVY is emtricitabine; tenofovir alafenamide fumarate. There are eighteen drug master file entries for this API. Additional details are available on the emtricitabine; tenofovir alafenamide fumarate profile page.

GENVOYA

Generic name: cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate
NCE-1 Date: November 2019

GENVOYA is a drug marketed by Gilead Sciences Inc. There are thirteen patents protecting this drug.

This drug has six hundred and forty-two patent family members in sixty countries. There has been litigation on patents covering GENVOYA

See drug price trends for GENVOYA.

The generic ingredient in GENVOYA is cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate. There are five drug master file entries for this API. Additional details are available on the cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate profile page.

ODEFSEY

Generic name: emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate
NCE-1 Date: November 2019

ODEFSEY is a drug marketed by Gilead Sciences Inc. There are eleven patents protecting this drug.

This drug has five hundred and twenty patent family members in sixty-one countries. There has been litigation on patents covering ODEFSEY

See drug price trends for ODEFSEY.

The generic ingredient in ODEFSEY is emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate. There are eighteen drug master file entries for this API. Additional details are available on the emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate profile page.

SYMTUZA

Generic name: cobicistat; darunavir ethanolate; emtricitabine; tenofovir alafenamide fumarate
NCE-1 Date: November 2019

Drug Price Trends for SYMTUZA
SYMTUZA is a drug marketed by Janssen Prods. There are thirteen patents protecting this drug.

This drug has six hundred and twenty-nine patent family members in fifty-nine countries. There has been litigation on patents covering SYMTUZA

See drug price trends for SYMTUZA.

The generic ingredient in SYMTUZA is cobicistat; darunavir ethanolate; emtricitabine; tenofovir alafenamide fumarate. There are five drug master file entries for this API. Additional details are available on the cobicistat; darunavir ethanolate; emtricitabine; tenofovir alafenamide fumarate profile page.

VEMLIDY

Generic name: tenofovir alafenamide fumarate
NCE-1 Date: November 2019

Drug Price Trends for VEMLIDY
VEMLIDY is a drug marketed by Gilead Sciences Inc. There are four patents protecting this drug.

This drug has one hundred and twenty-eight patent family members in forty-nine countries. There has been litigation on patents covering VEMLIDY

See drug price trends for VEMLIDY.

The generic ingredient in VEMLIDY is tenofovir alafenamide fumarate. There are forty-two drug master file entries for this API. Additional details are available on the tenofovir alafenamide fumarate profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Clients in 66 Countries

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
QuintilesIMS
Harvard Business School
Queensland Health
Moodys
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.